hydroxychloroquine has been researched along with Diabetes Mellitus, Type 1 in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine is an immunomodulatory drug that has been used for the treatment of malaria and autoimmune diseases." | 2.66 | Potential Effect of Hydroxychloroquine in Diabetes Mellitus: A Systematic Review on Preclinical and Clinical Trial Studies. ( Adamu, BA; Desalegn, TZ; Tsige, AG; Wondafrash, DZ; Yimer, EM; Zewdie, KA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, AS | 1 |
| Alotaibi, WS | 1 |
| Aldubayan, MA | 1 |
| Alhowail, AH | 1 |
| Al-Najjar, AH | 1 |
| Chigurupati, S | 1 |
| Elgharabawy, RM | 1 |
| Libman, I | 1 |
| Bingley, PJ | 1 |
| Becker, D | 1 |
| Buckner, JH | 1 |
| DiMeglio, LA | 1 |
| Gitelman, SE | 1 |
| Greenbaum, C | 1 |
| Haller, MJ | 1 |
| Ismail, HM | 1 |
| Krischer, J | 1 |
| Moore, WV | 1 |
| Moran, A | 1 |
| Muir, AB | 1 |
| Raman, V | 1 |
| Steck, AK | 1 |
| Toledo, FGS | 1 |
| Wentworth, J | 1 |
| Wherrett, D | 1 |
| White, P | 1 |
| You, L | 1 |
| Herold, KC | 1 |
| Wondafrash, DZ | 1 |
| Desalegn, TZ | 1 |
| Yimer, EM | 1 |
| Tsige, AG | 1 |
| Adamu, BA | 1 |
| Zewdie, KA | 1 |
| Ruíz-Quiñonez, JA | 1 |
| Guzmán-Priego, CG | 1 |
| Nolasco-Rosales, GA | 1 |
| Tovilla-Zarate, CA | 1 |
| Flores-Barrientos, OI | 1 |
| Narváez-Osorio, V | 1 |
| Baeza-Flores, GDC | 1 |
| Gonzalez-Castro, TB | 1 |
| López-Brito, CR | 1 |
| Denis-García, CA | 1 |
| Pérez-García, A | 1 |
| Juárez-Rojop, IE | 1 |
| Marchetti, M | 1 |
| Baker, MG | 1 |
| Noland, MM | 1 |
| Goucha, S | 1 |
| Khaled, A | 1 |
| Kharfi, M | 1 |
| Fazaa, B | 1 |
| Zermani, R | 1 |
| Ben Jilani, S | 1 |
| Kamoun, MR | 1 |
| Emami, J | 1 |
| Pasutto, FM | 1 |
| Mercer, JR | 1 |
| Jamali, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis[NCT01132118] | Phase 3 | 30 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 58.1 | 59.4 | 1.3 |
| Placebo | 58.1 | 60.3 | 2.2 |
HOMA-B = (360 x Insulin)/(Glucose - 63) (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mIU x dL)/(L x mg) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 116.5 | 110.8 | -5.8 |
| Placebo | 116.5 | 109.7 | -6.8 |
"We will examine the effect of HCQ on HOMA-IR during the active treatment phase compared with placebo phase.~HOMA-IR = (Glucose x insulin)/405" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mg x mIU)/(dL*L) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 2.0 | 1.7 | -0.3 |
| Placebo | 2.0 | 1.6 | -0.42 |
"We will examine the effect of HCQ on the Matsuda Insulin Sensitivity Index (ISI) during the active treatment phase compared with placebo phase.~ISI is based on insulin and glucose levels in a fasting state during an oral glucose tolerance test (OGTT) and is calculated as follows:~ISI (Matsuda) = 10000/√ G0 X I0 X Gmean X Imean~G0 - fasting plasma glucose (mg/dL) I0 - fasting plasma insulin (mIU/L) Gmean - mean plasma glucose during OGTT (mg/dL) Imean - mean plasma insulin during OGTT (mIU/L)" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (dL x L)/(mg x mIU) (Mean) | ||
|---|---|---|---|
| Baseline | Period Value | Change | |
| Hydroxychloroquine | 7.7 | 8.1 | 0.4 |
| Placebo | 7.7 | 7.8 | 0.14 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 114.1 | 101.7 | -12.4 |
| Placebo | 114.1 | 109.9 | -4.2 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 192.4 | 179.7 | -12.7 |
| Placebo | 192.4 | 189.4 | -3.0 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 100.6 | 92.4 | -8.2 |
| Placebo | 100.6 | 95.6 | -5.0 |
1 review available for hydroxychloroquine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Potential Effect of Hydroxychloroquine in Diabetes Mellitus: A Systematic Review on Preclinical and Clinical Trial Studies.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hy | 2020 |
6 other studies available for hydroxychloroquine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Factors Affecting the Incidence, Progression, and Severity of COVID-19 in Type 1 Diabetes Mellitus.
Topics: Adult; Biomarkers; Blood Cell Count; Blood Glucose; Blood Sedimentation; C-Reactive Protein; Comorbi | 2021 |
Hydroxychloroquine in Stage 1 Type 1 Diabetes.
Topics: Autoantibodies; Diabetes Mellitus, Type 1; Glucose; Humans; Hydroxychloroquine; Insulin | 2023 |
Features of patients that died for COVID-19 in a hospital in the south of Mexico: A observational cohort study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 1; Female; Hos | 2021 |
Treatment of subcutaneous sarcoidosis with hydroxychloroquine: report of 2 cases.
Topics: Adrenal Cortex Hormones; Biopsy; Contraindications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty | 2014 |
Granuloma annulare.
Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Infective Agents; Antirh | 2008 |
Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats.
Topics: Animals; Cytosol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Enzyme Inhibitors; Hyd | 1999 |